Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.51 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189952 | 1.00 | F2RL3 (0.51) | F2RL3GLRA3TP53THRBALDH1A1 | |
| SCHEMBL19783267 | 0.82 | GLRA3 (0.47) | F2RL3GLRA3TP53THRBALDH1A1 | |
| SCHEMBL30187576 | 0.81 | F2RL3 (0.63) | F2RL3GLRA3TP53THRBALDH1A1 | |
| SCHEMBL19782614 | 0.81 | F2RL3 (0.63) | F2RL3GLRA3TP53THRBALDH1A1 | |
| SCHEMBL19782739 | 0.79 | F2RL3 (0.34) | F2RL3TP53TDP1MAPTHTT | |
| SCHEMBL21379388 | 0.79 | F2RL3 (0.76) | F2RL3GLRA3TP53THRBALDH1A1 | |
| SCHEMBL19783277 | 0.79 | F2RL3 (0.74) | F2RL3GLRA3TP53TDP1MAPT | |
| SCHEMBL19783425 | 0.78 | F2RL3 (0.73) | F2RL3GLRA3 | |
| SCHEMBL19783071 | 0.78 | F2RL3 (0.85) | F2RL3 | |
| SCHEMBL21379471 | 0.78 | F2RL3 (0.73) | F2RL3GLRA3TP53ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | F2RL3 2/4885GLRA3 1238/4885TP53 2258/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | F2RL3 2/4885GLRA3 999/4885TP53 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.